Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct:108:105291.
doi: 10.1016/j.ebiom.2024.105291. Epub 2024 Oct 3.

Alzheimer's disease biomarkers and the tyranny of treatment

Jason Karlawish  1 , Joshua D Grill  2
Affiliations
Review

Alzheimer's disease biomarkers and the tyranny of treatment

Jason Karlawish et al. EBioMedicine. 2024 Oct.

Abstract

Advances in treatment are changing not only the therapeutic options for patients with Alzheimer's disease; they're also changing their diagnostic options. Technologies to detect amyloid such as PET imaging and blood or CSF testing now have a central role in Alzheimer's disease care. Notably, this role has been made possible by regulatory approval and coverage by payers of therapies. Access to treatments and the diagnostic tests needed to prescribe them is encourageing but it reveals a problem. These tests are tailored to the needs of the therapies, not to the needs of patients. Patients and families need to understand the causes of their impairments and their prognosis. This requires access to the best available diagnostic tests and this access should not depend on the availability of treatments. These tests should be used to their fullest capacity to inform patients of the causes of their cognitive impairments and their prognosis. Unfortunately, compared to diagnostic testing, treatment options are overvalued. We call this problem the tyranny of treatment.

Keywords: Alzheimer; Biomarker.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Dr Grill reported grants from the National Institute on Aging (AG066519), Alzheimer's Association, BrightFocus Foundation, Lilly, Biogen, Genentech, and Eisai and personal fees from SiteRx. Dr Karlawish reported grants from the National Institute on Aging (P30-AG-072979, U54-AG-063546, and U24-AG-057437), Biogen, Lilly, and Novartis. He served on the scientific advisory board for Linus Health and the board of directors for Greenwall Foundation.

References

    1. Rabinovici G.D., Gatsonis C., Apgar C., et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286–1294. - PMC - PubMed
    1. Wolk D.A., Sadowsky C., Safirstein B., et al. Use of flutemetamol F 18-labeled positron emission tomography and other biomarkers to assess risk of clinical progression in patients with amnestic mild cognitive impairment. JAMA Neurol. 2018 Sep 1;75(9):1114–1123. - PMC - PubMed
    1. Vos S.J., Verhey F., Frolich L., et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327–1338. - PMC - PubMed
    1. Ong K.T., Villemagne V.L., Bahar-Fuchs A., et al. Abeta imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. J Neurol Neurosurg Psychiatr. 2015;86(4):431–436. - PubMed
    1. Grill J.D., Cox C.G., Kremen S., et al. Patient and caregiver reactions to clinical amyloid imaging. Alzheimers Dement. 2017;13(8):924–932. - PMC - PubMed